Anifrolumab Treatment Improves Quality of Life and Decreases Systemic Corticosteroid Use in Patients with Systemic Lupus Erythematosus

The study investigated the effects of Anifrolumab on patients with systemic lupus erythematosus (SLE) through qualitative interviews and electronic medical records. Conducted with 14 patients for interviews and 16 for medical data, the study found significant improvements in symptoms such as fatigue, joint pain, and hair loss, as well as in daily life impacts like physical activity and social life. Disease activity and corticosteroid use decreased, while laboratory results improved. These findings highlight Anifrolumab's efficacy in alleviating both subjective symptoms and objective disease parameters in SLE patients.